Ra Capital Management, L.P.

Q1 2025 13F Holdings Report, Stock Holdings

Signature - Title
Rajeev Shah - Authorized Signatory
Location
Boston, MA
Holdings as of
31 Mar 2025
Value $
$5.99B
Num holdings
85
Filing time
15 May 2025, 16:44:59
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included ASND, PCVX, RYTM, JANX, and NAMS.
Previous filing
Q4 2024 - 14 Feb 2025
Next filing
Q2 2025 - 14 Aug 2025
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2025 Q1 compared to 2024 Q4 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Rajeev Shah Authorized Signatory Boston, Massachusetts 15 May 2025

The shares of Climb Bio, Inc. listed in the Information Table with "OTR" investment discretion represent shares held by Sera Medicines, LLC ("Sera"). Funds advised by the Reporting Manager collectively own approximately 76.60% of the outstanding equity interests of Sera that would share in distributions of the shares of Climb Bio, Inc. or proceeds derived therefrom. Investment discretion with respect to the shares held by Sera is shared with individuals not affiliated with the Reporting Manager.